On February 2, 2016, the Patent Trial and Appeal Board (PTAB) rejected another petition by generic-drug maker Lannett Holdings, which urged the PTAB to review claims of Finnegan client AstraZeneca’s Zomig nasal spray patent. The PTAB denied the petition for inter partes review (IPR) because it was filed too late–more than a year after Lannett was served a district court complaint asserting that the company had infringed the patent. The week prior, the PTAB handed down a similar ruling against Lannett, finding that its IPR petition for another Zomig patent (asserted in the same litigation) was also time-barred.